Company Overview and News

5
Is NASH Really a $35 Billion Opportunity?

2018-09-26 biospace - 1
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize?
TBRA MDGL VKTXW GILD ICPT VKTX

 
Allergan/Tobira And Cenicriviroc: The Overlooked And Misunderstood Immune Modulatory Anti-NASH Drug Candidate

2018-07-06 seekingalpha
Faced with the potential loss of patent exclusivity on blockbuster eye-medication Restasis, Allergan will be reliant on innovative future/imminent bestseller drug candidates for new organic growth and to remain competitive.
TBRA MYL AGN ACT

3
WindMIL Therapeutics Raises $32.53 Million

2018-06-18 biospace
WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing. The Series B round was led by QiMing USA Venture Partners, the new U.S. entity of China company QMing. There was a Series A round worth $11 million.
TBRA AUXL

61
Viking Therapeutics: Hallmark Moment

2018-06-13 seekingalpha - 2
Viking Therapeutics experienced a "Hallmark moment" when its shares shot up 100% in a single session, piggybacking on Madrigal's data. Is the "sympathy move" more deserving of condolences or congratulations?
TBRA MDGL VKTXW GNFTF ICPT VKTX

220
Alpine Immune Sciences: What The Q1 2018 Earnings Foretell?

2018-06-07 seekingalpha
Alpine is a stellar young grower hitting its next growth inflection, as reflected by various corporate developments. Strong earnings report with significant catalysts to boost the share price.
TBRA AMGN CELGZ AGN GILD CELG NVS KITE ALPN

87
Icahn buys small stake in drugmaker Allergan: sources

2018-06-06 channelnewsasia
Billionaire investor Carl Icahn has acquired a small stake in Allergan Plc at a time when the drugmaker is under pressure from other activist shareholders, people familiar with the matter said on Wednesday.
TBRA PFZ ZLTQ AGN FRX ACT 500680 PFE PFIZER

87
Icahn buys small stake in drugmaker Allergan: sources

2018-06-06 reuters
(Reuters) - Billionaire investor Carl Icahn has acquired a small stake in Allergan Plc (AGN.N) at a time when the drugmaker is under pressure from other activist shareholders, people familiar with the matter said on Wednesday.
TBRA PFZ ZLTQ AGN FRX ACT 500680 PFE PFIZER

72
Reader Inquiry: AnaptysBio, Is It Time For Round 2 With This Former ROTY Winner?

2018-05-28 seekingalpha
We logged a decent gain in the ROTY 10 stock model account by playing the runup on this one in 2017.
TBRA ANAB MRTX

71
Esmya Restriction In Europe Could Handcuff Allergan

2018-05-21 seekingalpha
AGN is seeking FDA approval for Esmya in the U.S. EMA findings could jeopardize FDA approval or hurt Esmya sales.
TBRA VTAE AGN GEDRY

162
Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant

2018-05-11 seekingalpha
Alpine is leveraging on its stellar therapeutic innovation platforms (TIP and vIgD) to deliver the next-generation immuno-oncology (I-O) therapeutics.
SGEN TBRA JAZZ AMGN CELGZ GILD MRK CELG NVS KITE ALPN

84
Aptose Announces Appointment of Caroline M. Loewy to Board of Directors

2018-04-25 globenewswire
SAN DIEGO and TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Caroline M. Loewy to the Board of Directors effective immediately. Aptose’s Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development.
TBRA ACHV PARD CORT PARDP APTO APS MS CBAY

10
Startup Terns Secures Three NASH Assets From Eli Lilly

2018-04-04 biospace
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
TBRA GILD

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TBRA / Tobira Therapeutics, Inc. on message board site Silicon Investor.

Fatbrain.com Inc. (FATB) Fatbrain.com Inc. (FATB) Fatbrain.com Inc. (FATB) FatBrain.com (FATB) Is your head big enough?? FatBrain.com (FATB) Is your head big enough?? FatBrain.com (FATB) Is your head big enough??
CUSIP: 88883P101